J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Immunocore reports third quarter financial results and provides a business updateKIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter ...

After all, who doesn’t enjoy watching a hero dodge lasers, traverse lava pits, or unleash a well-timed combo just to take down that one guy ... he’s a villain who straddles the line between comical ...

These benefits could potentially shave years off our development time line in GBM and make the asset significantly ... Remarkable potency in the nanomolar range for multiple blood cancer types, but ...

PureWow editors select every item that appears on this page, and some items may be gifted to us. Additionally, PureWow may ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy ...

Roche announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San ...

It’s time to see what’s next for The Bloodline, with Sami Zayn invited to the show to try to figure out where he stands with ...

Canada Classic have a shot at winning a maiden title at the World Rugby Classic after holding off last year’s champions ...

Healthcare stocks performed well during Trump's first term, despite increased uninsured rates and reduced regulation. Click ...